Concord Drugs Ltd
NSE: BSE: 538965
₹83.93
(1.24%)
Mon, 01 Jun 2026, 03:42 pm
Market Cap0
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KConcord Drugs Analysis
dividend
- Unable to evaluate Concord Drugs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Concord Drugs's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Concord Drugs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Concord Drugs is profitable, therefore cash runway is not a concern.
- Concord Drugs is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (26.1%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 6.2x debt.
- Concord Drugs's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (115.9% vs 42.1% today).
- Interest payments on debt are not well covered by earnings (EBIT is 1.4x annual interest expense, ideally 3x coverage).
- Concord Drugs's level of debt (42.1%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Concord Drugs board of directors is about average.
misc
- Concord Drugs is not covered by any analysts.
past
- Concord Drugs's 1-year earnings growth exceeds its 5-year average (541% vs -30.4%)
- Concord Drugs's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (541% vs 22.7%).
- Concord Drugs's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
- Concord Drugs used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Concord Drugs's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Concord Drugs has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- Concord Drugs's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Concord Drugs is good value based on assets compared to the IN Pharmaceuticals industry average.
- Concord Drugs's share price is below the future cash flow value, but not at a substantial discount (< 40%).
- Concord Drugs is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Concord Drugs is overvalued based on earnings compared to the India market.
- 538965 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 538965 underperformed the Market in India which returned -14.5% over the past year.
- BSE:538965 is down -11.1% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:538965 is down -11.1% underperforming the market in India which returned 8% over the past month.